Why the study?
The long-term influence of metabolic syndrome on paroxysmal AF recurrence after a single cryoballoon ablation procedure was scarcely investigated in a Chinese population.
Does metabolic syndrome increase the risk of atrial fibrillation recurrence in paroxysmal AF patients after a single cryoballoon ablation procedure?
Does metabolic syndrome increase the risk of atrial fibrillation recurrence in paroxysmal AF patients after a single cryoballoon ablation procedure?
Metabolic syndrome is an independent predictor of long-term atrial fibrillation recurrence after cryoballoon ablation, suggesting that managing metabolic risk factors may improve ablation outcomes.
MetS may flag higher long-term recurrence risk after cryoballoon ablation; leaves open whether MetS modification alters outcomes.
BACKGROUND: Metabolic syndrome (MetS) has been reported as a risk factor of atrial fibrillation (AF) recurrence after radiofrequency catheter ablation. This study aimed to investigate the long-term influence of MetS on paroxysmal AF recurrence after a single cryoballoon ablation procedure, which was scarcely investigated yet in Chinese population. METHODS: In total, 137 paroxysmal AF patients who had successfully completed a single cryoballoon ablation procedure at Fuwai Hospital, Beijing, China from December 2013 to October 2015 were enrolled. Excepting for patients with AF recurrence, all patients were followed up for no less than five years. Independent predictors of AF recurrence were determined by Cox proportional hazards regression analysis. RESULTS: = 0.030) was an independent predictor of AF recurrence after adjusting for multiple factors. After the second year post cryoballoon ablation procedure, the recurrence rate of AF gradually increased in patients with MetS, in contrast, decreased recurrence rate of AF in patients without MetS. CONCLUSIONS: MetS is an independent predictor for five-year AF recurrence after a single cryoballoon ablation procedure in paroxysmal AF patients. Combination therapy of AF and MetS may improve the long-term outcomes of AF patients.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: